文献速递系统性红斑狼疮

CAR-T细胞疗法治疗系统性红斑狼疮:一项系统综述

CAR T-cell therapy in SLE: A systematic review.
PubMed 文献 · Semin Arthritis Rheum · 2025-07-16

该系统综述遵循PRISMA推荐,检索MEDLINE、Embase、Scopus和CENTRAL,纳入16项研究共145例接受CAR-T治疗的SLE患者。汇总分析显示,102例可获取的SLEDAI评分均值从基线13.1(95%CI 12.3-13.9)降至6个月时2.3(95%CI 1.5-3.1)和12个月时1.4(95%CI 0.3-2.4);45/64例(70%)达到DORIS缓解,50/56例(89%)达到LLDAS。细胞因子释放综合征(CRS)发生于81例(56%),其中80例(98%)为1级或2级,1例(2%)为3级;免疫效应细胞相关神经毒性综合征(ICANS)报告4例;11例(7.6%)发生严重感染,包括1例致死性肺炎链球菌脑膜炎。

要点

  • 汇总102例SLEDAI评分,均值从基线13.1降至6个月2.3和12个月1.4。
  • 45/64例(70%)达到DORIS缓解,50/56例(89%)达到LLDAS。
  • CRS发生于81例(56%),其中80例(98%)为1级或2级,1例(2%)为3级;ICANS报告4例;11例(7.6%)发生严重感染,含1例致死性肺炎链球菌脑膜炎。

核心结论

  • 该系统综述评估了CAR-T细胞疗法治疗SLE患者的所有现有临床证据,结果强化了该治疗模式的疗效,并强调需要进一步研究以更好地界定其在SLE管理中的作用。

研究设计与样本

  • 遵循PRISMA推荐的系统综述,检索MEDLINE(PubMed)、Embase、Scopus和CENTRAL,纳入16项研究共145例参与者。

主要发现

  • 汇总102例可获取的个体SLEDAI评分,均值从基线13.1(95%CI 12.3-13.9)降至6个月时2.3(95%CI 1.5-3.1)和12个月时1.4(95%CI 0.3-2.4)。
  • 45/64例(70%)达到DORIS缓解,50/56例(89%)达到LLDAS。
  • CRS发生于81例(56%),其中80例(98%)为1级或2级,1例(2%)为3级。
  • ICANS报告4例:1级1例、2级1例、3级1例、4级1例。
  • 11例(7.6%)发生严重感染,包括1例致死性肺炎链球菌脑膜炎。

关键数值与推荐

  • DORIS缓解:45/64例(70%)。
  • LLDAS:50/56例(89%)。
  • SLEDAI均值:基线13.1(95%CI 12.3-13.9),6个月2.3(95%CI 1.5-3.1),12个月1.4(95%CI 0.3-2.4)。

局限性

  • 原文结论指出需要进一步研究以更好地界定CAR-T细胞疗法在SLE管理中的作用。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: CAR T-cell therapy is poised to revolutionize the treatment of SLE. Several publications reported on small numbers of SLE patients treated with CAR-T. OBJECTIVE: To review and summarize the available clinical evidence published or presented to date on the use of CAR therapy in SLE. METHODS: We conducted a systematic review to evaluate all clinical studies assessing safety and efficacy outcomes of CAR therapy in SLE. For this review, we followed PRISMA recommendations. MEDLINE (PubMed), Embase, Scopus, and CENTRAL were consulted. RESULTS: The search strategy yielded 5905 results, of which 16 studies were included, encompassing 145 participants. Pooled analysis of the 102 individual SLEDAI scores available showed the mean baseline SLEDAI of 13.1 (95% CI 12.3-13.9) decreased to 2.3 (95% CI 1.5-3.1) after 6 months, and 1.4 (95% CI 0.3-2.4) after 12 months. DORIS remission was achieved in 45/64 patients (70%) and LLDAS in 50/56 (89%). CRS occurred in 81 (56%) participants, of which 80 (98%) were grade 1 or 2, and 1 (2%) grade 3. ICANS was reported in four patients, 1 grade 1, 1 grade 2, 1 grade 3, and 1 grade 4. Eleven patients (7.6%) developed serious infections, including one case of fatal pneumococcal meningitis. CONCLUSION: This systematic review evaluated all the available clinical evidence on the use of CAR T-cell therapy in patients with SLE. The findings reinforce the efficacy of this treatment modality and underscore the need for further research to better define its role in SLE management.

来源:Semin Arthritis Rheum,查看原文。版权归原作者所有。

引用

  1. Nordmann-Gomes A, Khalili L, Tang W, et al. CAR T-cell therapy in SLE: A systematic review. Semin Arthritis Rheum. 2025. PMID: 40749440. doi:10.1016/j.semarthrit.2025.152786

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。